- \n
- Net Sales for the third quarter 2026 were $19.1 million representing a 20% increase over the same period in 2025<\/i><\/b><\/li>\n
- Gross Profit for the third quarter 2026 increased 37% over the same period in 2025 primarily driven by higher volumes<\/i><\/b><\/li>\n
- The combination of Rockwell Medical with Vantive\u2019s global hemodialysis concentrates, hemodialysis machines, water treatment systems, and related consumables and technical services business is projected to generate annual revenue between $400 million and $450 million<\/i><\/b><\/li>\n<\/ul>\n
WIXOM, Mich.–(BUSINESS WIRE<\/a>)–
\nRockwell Medical, Inc. (the \u201cCompany\u201d) (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three and nine months ended September 30, 2026.<\/p>\n\n\u201cWe have maintained solid upward momentum across our business, driven by robust market demand and disciplined execution,\u201d said Mark Strobeck, Ph.D.<\/a>, President and Chief Executive Officer at Rockwell Medical. \u201cOur third quarter 2026 net sales grew 20% year-over-year, reflecting strong customer adoption and market validation of our products. Our team\u2019s commitment to quality and reliable customer service continues to set us apart. We are excited to build on this momentum with our recently announced equity and asset purchase agreement with Vantive, a transformational step that we believe will significantly expand our portfolio and global reach. As we celebrate our 30th anniversary, we are well-positioned to drive innovation and capitalize on emerging growth opportunities.\u201d<\/p>\n
FINANCIAL HIGHLIGHTS<\/b><\/p>\n
Net Sales<\/span><\/p>\n
- \n
- \nNet sales for the three months ended September 30, 2026 were $19.1 million, which represents a 20% increase over net sales of $15.9 million for the same period in 2025. The increase in net sales was driven by greater purchasing from our existing customers and additional sales to new customers in the western United States.<\/p>\n<\/li>\n
- \nNet sales for the nine months ended September 30, 2026 were $54.2 million, which represents a 7% increase over net sales of $50.9 million for the same period in 2025.<\/p>\n<\/li>\n<\/ul>\n
Gross Profit<\/span><\/p>\n
- \n
- \nGross profit for the three months ended September 30, 2026 was $3.1 million, which represents a 37% increase over gross profit for the same period in 2025.<\/p>\n<\/li>\n
- \nGross profit for the nine months ended September 30, 2026 was $9.3 million, which represents an 18% increase over gross profit of $7.8 million for the same period in 2025.<\/p>\n<\/li>\n<\/ul>\n
Gross Margin<\/span><\/p>\n
- \n
- \nGross margin for the three months ended September 30, 2026 was 16%, which represents an increase from 14% for the same period in 2025.<\/p>\n<\/li>\n
- \nGross margin for the nine months ended September 30, 2026 was 17%, which represented an increase from 15% for the same period in 2025.<\/p>\n<\/li>\n<\/ul>\n
Net Loss<\/span><\/p>\n
- \n
- \nNet loss for the three months ended September 30, 2026 was $2.3 million compared to a net loss of $1.8 million for the same period in 2025.<\/p>\n<\/li>\n
- \nNet loss for the nine months ended September 30, 2026 was $5.1 million compared to a net loss of $4.8 million for the same period in 2025.<\/p>\n<\/li>\n<\/ul>\n
Adjusted EBITDA<\/span><\/p>\n
- \n
- \nAdjusted EBITDA for the three months ended September 30, 2026 was ($0.3) million compared to Adjusted EBITDA of $50,000 for the same period in 2025.<\/p>\n<\/li>\n
- \nAdjusted EBITDA for the nine months ended September 30, 2026 was ($0.7) million compared with Adjusted EBITDA of ($0.6) million for the same period in 2025.<\/p>\n<\/li>\n<\/ul>\n
Cash, Cash Equivalents and Investments Available-for-Sale<\/span><\/p>\n
- \n
- \nCash, cash equivalents and investments available-for-sale at September 30, 2026 was $22.5 million, which represents a decrease from $24.8 million at June 30, 2026. The decrease was primary driven by an increase in accounts receivable and prepaid expenses in the ordinary course of business, as well as capital purchases to further automate our manufacturing facilities.<\/p>\n<\/li>\n<\/ul>\n
- Gross Profit for the third quarter 2026 increased 37% over the same period in 2025 primarily driven by higher volumes<\/i><\/b><\/li>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20261112177722\/en\/2968617\/3\/Rockwell_Medical_-_logo_-_BusinessWire.jpg\"){kind=logo}
<\/td>\n<\/tr>\n